Morel O, Marchandot B, Jesel L, Sattler L, Trimaille A, Curtiaud A, Ohana M, Fafi-Kremer S, Schini-Kerth V, Grunebaum L, and Freyssinet JM
Procoagulant microparticles are associated with the extent of lung injuries in #COVID19 and pulmonary thrombosis https://bit.ly/3eX2LPc., Competing Interests: Conflict of interest: O. Morel has nothing to disclose. Conflict of interest: B. Marchandot has nothing to disclose. Conflict of interest: L. Jesel has nothing to disclose. Conflict of interest: L. Sattler has nothing to disclose. Conflict of interest: A. Trimaille has nothing to disclose. Conflict of interest: A. Curtiaud has nothing to disclose. Conflict of interest: M. Ohana has nothing to disclose. Conflict of interest: S. Fafi-Kremer has nothing to disclose. Conflict of interest: V. Schini-Kerth has nothing to disclose. Conflict of interest: L. Grunebaum has nothing to disclose. Conflict of interest: J-M. Freyssinet reports other (royalties) from HYPHEN BioMed, during the conduct of the study; In addition, Dr. Freyssinet has a patent WO1996003655A1 with royalties paid to HYPHEN BioMed and Patent WO1996003655A1 expired several years ago, in 2013–2014 as far as it can be remembered, when giving up paying for yearly fees no longer covered by royalties from HYPHEN BioMed for their Zymuphen MP-activity kits. For instance, patent fee for 2012 was 1902.83 EUR for France and Germany only, not including Japan and US rights. Last royalties, over 36 months (3 years) amounted to 5153 EUR, submitted to 16% taxes paid to the French tax system., (Copyright ©The authors 2021.)